Zuckerman Israeli Postdoctoral Scholar Tal Gilboa (Alum), one of three inventors from the Technion Research and Development Foundation, to receive a patent for a method quantifying a first species of RNA within a sample, investigating individual macromolecules, e.g. by translocation through nanopores.
The ability to sense and digitally count individual RNA and mRNA biomarker molecules holds a great potential for early diagnosis of a wide range of diseases including the recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. The ‘gold-standard’ method for RNA molecule quantification in clinical samples relies on reverse transcription, followed by a massive non-linear amplification of the DNA molecules using Reverse Transcription quantitative Real-Time Polymerase Chain Reaction (RT qRT-PCR). RT qRT-PCR relies on bulk fluorescence signal measurement during the annealing step of each PCR amplification cycle.